Literature DB >> 22890713

Neurocardiac dysregulation and neurogenic arrhythmias in a transgenic mouse model of Huntington's disease.

Helen Kiriazis1, Nicole L Jennings, Pamela Davern, Gavin Lambert, Yidan Su, Terence Pang, Xin Du, Luisa La Greca, Geoffrey A Head, Anthony J Hannan, Xiao-Jun Du.   

Abstract

Huntington's disease (HD) is a heritable neurodegenerative disorder, with heart disease implicated as one major cause of death. While the responsible mechanism remains unknown, autonomic nervous system (ANS) dysfunction may play a role. We studied the cardiac phenotype in R6/1 transgenic mice at early (3 months old) and advanced (7 months old) stages of HD. While exhibiting a modest reduction in cardiomyocyte diameter, R6/1 mice had preserved baseline cardiac function. Conscious ECG telemetry revealed the absence of 24-h variation of heart rate (HR), and higher HR levels than wild-type littermates in young but not older R6/1 mice. Older R6/1 mice had increased plasma level of noradrenaline (NA), which was associated with reduced cardiac NA content. R6/1 mice also had unstable R-R intervals that were reversed following atropine treatment, suggesting parasympathetic nervous activation, and developed brady- and tachyarrhythmias, including paroxysmal atrial fibrillation and sudden death. c-Fos immunohistochemistry revealed greater numbers of active neurons in ANS-regulatory regions of R6/1 brains. Collectively, R6/1 mice exhibit profound ANS-cardiac dysfunction involving both sympathetic and parasympathetic limbs, that may be related to altered central autonomic pathways and lead to cardiac arrhythmias and sudden death.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22890713      PMCID: PMC3528995          DOI: 10.1113/jphysiol.2012.238113

Source DB:  PubMed          Journal:  J Physiol        ISSN: 0022-3751            Impact factor:   5.182


  58 in total

1.  Cardiac sympathetic nerve function in congestive heart failure.

Authors:  G Eisenhofer; P Friberg; B Rundqvist; A A Quyyumi; G Lambert; D M Kaye; I J Kopin; D S Goldstein; M D Esler
Journal:  Circulation       Date:  1996-05-01       Impact factor: 29.690

2.  Aberrant heart rate and brainstem brain-derived neurotrophic factor (BDNF) signaling in a mouse model of Huntington's disease.

Authors:  Kathleen J Griffioen; Ruiqian Wan; Tashalee R Brown; Eitan Okun; Simonetta Camandola; Mohamed R Mughal; Terry M Phillips; Mark P Mattson
Journal:  Neurobiol Aging       Date:  2011-12-31       Impact factor: 4.673

3.  Parasympathetic inhibition of sympathetic effects on sinus rate in anesthetized dogs.

Authors:  Y Furukawa; Y Hoyano; S Chiba
Journal:  Am J Physiol       Date:  1996-07

4.  Disintegration of the sleep-wake cycle and circadian timing in Huntington's disease.

Authors:  A Jennifer Morton; Nigel I Wood; Michael H Hastings; Carrie Hurelbrink; Roger A Barker; Elizabeth S Maywood
Journal:  J Neurosci       Date:  2005-01-05       Impact factor: 6.167

5.  The power of automated high-resolution behavior analysis revealed by its application to mouse models of Huntington's and prion diseases.

Authors:  Andrew D Steele; Walker S Jackson; Oliver D King; Susan Lindquist
Journal:  Proc Natl Acad Sci U S A       Date:  2007-01-29       Impact factor: 11.205

6.  Autonomic symptoms in patients and pre-manifest mutation carriers of Huntington's disease.

Authors:  N A Aziz; G V Anguelova; J Marinus; J G van Dijk; R A C Roos
Journal:  Eur J Neurol       Date:  2010-02-24       Impact factor: 6.089

7.  Neural substrate for atrial fibrillation: implications for targeted parasympathetic blockade in the posterior left atrium.

Authors:  Rishi Arora; Joseph S Ulphani; Roger Villuendas; Jason Ng; Laura Harvey; Sarah Thordson; Firdous Inderyas; Yi Lu; David Gordon; Pablo Denes; Rodney Greene; Susan Crawford; Robert Decker; Alexander Morris; Jeffrey Goldberger; Alan H Kadish
Journal:  Am J Physiol Heart Circ Physiol       Date:  2007-11-02       Impact factor: 4.733

8.  Mice with cardiac-restricted angiotensin-converting enzyme (ACE) have atrial enlargement, cardiac arrhythmia, and sudden death.

Authors:  Hong D Xiao; Sebastien Fuchs; Duncan J Campbell; William Lewis; Samuel C Dudley; Vijaykumar S Kasi; Brian D Hoit; George Keshelava; Hui Zhao; Mario R Capecchi; Kenneth E Bernstein
Journal:  Am J Pathol       Date:  2004-09       Impact factor: 4.307

9.  Cardiomyocyte expression of a polyglutamine preamyloid oligomer causes heart failure.

Authors:  J Scott Pattison; Atsushi Sanbe; Alina Maloyan; Hanna Osinska; Raisa Klevitsky; Jeffrey Robbins
Journal:  Circulation       Date:  2008-05-19       Impact factor: 29.690

10.  Baroreceptor reflex dysfunction in the BACHD mouse model of Huntington's disease.

Authors:  Analyne M Schroeder; Dawn H Loh; Maria C Jordan; Kenneth P Roos; Christopher S Colwell
Journal:  PLoS Curr       Date:  2011-11-04
View more
  27 in total

1.  Circadian dysfunction in the Q175 model of Huntington's disease: Network analysis.

Authors:  Benjamin Smarr; Tamara Cutler; Dawn H Loh; Takashi Kudo; Dika Kuljis; Lance Kriegsfeld; Cristina A Ghiani; Christopher S Colwell
Journal:  J Neurosci Res       Date:  2019-07-29       Impact factor: 4.164

2.  PCP4 regulates Purkinje cell excitability and cardiac rhythmicity.

Authors:  Eugene E Kim; Akshay Shekhar; Jia Lu; Xianming Lin; Fang-Yu Liu; Jie Zhang; Mario Delmar; Glenn I Fishman
Journal:  J Clin Invest       Date:  2014-10-08       Impact factor: 14.808

3.  Huntington's Disease-Induced Cardiac Disorders Affect Multiple Cellular Pathways.

Authors:  Girish C Melkani
Journal:  React Oxyg Species (Apex)       Date:  2016-09

Review 4.  Systemic manifestation and contribution of peripheral tissues to Huntington's disease pathogenesis.

Authors:  Chia-Lung Chuang; Fabio Demontis
Journal:  Ageing Res Rev       Date:  2021-05-09       Impact factor: 11.788

5.  Three Huntington's Disease Specific Mutation-Carrying Human Embryonic Stem Cell Lines Have Stable Number of CAG Repeats upon In Vitro Differentiation into Cardiomyocytes.

Authors:  Laureen Jacquet; Andreas Neueder; Gabor Földes; Panagiotis Karagiannis; Carl Hobbs; Nelly Jolinon; Maxime Mioulane; Takao Sakai; Sian E Harding; Dusko Ilic
Journal:  PLoS One       Date:  2015-05-20       Impact factor: 3.240

6.  Right ventricular dysfunction in the R6/2 transgenic mouse model of Huntington's disease is unmasked by dobutamine.

Authors:  Guido Buonincontri; Nigel I Wood; Simon G Puttick; Alex O Ward; T Adrian Carpenter; Stephen J Sawiak; A Jennifer Morton
Journal:  J Huntingtons Dis       Date:  2014

Review 7.  Purine Nucleotides Metabolism and Signaling in Huntington's Disease: Search for a Target for Novel Therapies.

Authors:  Marta Tomczyk; Talita Glaser; Ewa M Slominska; Henning Ulrich; Ryszard T Smolenski
Journal:  Int J Mol Sci       Date:  2021-06-18       Impact factor: 5.923

8.  Huntington's disease induced cardiac amyloidosis is reversed by modulating protein folding and oxidative stress pathways in the Drosophila heart.

Authors:  Girish C Melkani; Adriana S Trujillo; Raul Ramos; Rolf Bodmer; Sanford I Bernstein; Karen Ocorr
Journal:  PLoS Genet       Date:  2013-12-19       Impact factor: 5.917

9.  Nitric oxide dysregulation in platelets from patients with advanced Huntington disease.

Authors:  Albino Carrizzo; Alba Di Pardo; Vittorio Maglione; Antonio Damato; Enrico Amico; Luigi Formisano; Carmine Vecchione; Ferdinando Squitieri
Journal:  PLoS One       Date:  2014-02-25       Impact factor: 3.240

10.  A broad phenotypic screen identifies novel phenotypes driven by a single mutant allele in Huntington's disease CAG knock-in mice.

Authors:  Sabine M Hölter; Mary Stromberg; Marina Kovalenko; Lillian Garrett; Lisa Glasl; Edith Lopez; Jolene Guide; Alexander Götz; Wolfgang Hans; Lore Becker; Birgit Rathkolb; Jan Rozman; Anja Schrewed; Martin Klingenspor; Thomas Klopstock; Holger Schulz; Eckhard Wolf; Wolfgang Wursta; Tammy Gillis; Hiroko Wakimoto; Jonathan Seidman; Marcy E MacDonald; Susan Cotman; Valérie Gailus-Durner; Helmut Fuchs; Martin Hrabě de Angelis; Jong-Min Lee; Vanessa C Wheeler
Journal:  PLoS One       Date:  2013-11-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.